<DOC>
	<DOCNO>NCT00969449</DOCNO>
	<brief_summary>To compare pharmacokinetic profile propose extended- release tablet naproxen sodium 660 mg relative two tablet Naprelan 500 mg follow single dose administration 36 hour fast condition</brief_summary>
	<brief_title>Pharmacokinetics Study Comparing Naproxen Sodium Extended Release Naprelan</brief_title>
	<detailed_description />
	<mesh_term>Naproxen</mesh_term>
	<criteria>Healthy male female subject 18 55 year age inclusive Body Mass Index ( BMI ) approximately 18 30 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) Results screen clinical laboratory test within normal range consider clinically significant Principal Investigator Sponsor Female subject childbearing potential must use medically acceptable form birth control least 1 month prior screen ( 3 month oral contraceptive ) , e.g. , oral patch contraceptive , intrauterine device , DepoProveraÂ® , double barrier negative pregnancy test Screening Day 0 Dosing Period . Female subject nonchildbearing potential must amenorrheic least 2 year hysterectomy and/or bilateral oophorectomy Be willing participate schedule visit , treatment plan , laboratory test trial procedure accord clinical protocol History hypersensitivity aspirin ( ASA ) , naproxen sodium , acetaminophen , similar pharmacological agent component product Females pregnant lactating Loss blood excess 500 ml within 56 day first dose trial treatment ( e.g. , donation , plasmapheresis injury ) History gastrointestinal bleeding perforation , relate previous NSAID therapy . Active , history recurrent peptic ulcer/hemorrhage ( two distinct episode proven ulceration bleeding ) Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic disease malignancy Positive alcohol drug test Screening Day 0 Dosing Period Have take medication ( except acceptable form birth control ) within 10 day prior dose throughout trial , unless opinion Investigator Sponsor , medication interfere trial procedure , data integrity , compromise safety subject Have take ASA , ASAcontaining product , acetaminophen ( acetylparaaminophenol APAP ) NSAID ( OTC prescription ) 7 day prior dose treatment period , trial treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Naproxen Sodium</keyword>
</DOC>